Forest plants Nabriva acquisition seed with $25M antibiotics deal
This article was originally published in Scrip
Executive Summary
Forest Laboratories has secured an option to acquire the Vienna-based Nabriva Therapeutics within the next 12 months, as part of a co-development deal covering the biotech's lead investigational antibacterial agent, BC-3781. Forest is paying Nabriva $25 million and has agreed to finance the development BC-3781, which is currently in Phase II, over the next 12 months. The companies expect to start Phase III trials with the lead compound in 2013.